Volume 91, Issue 3, (December 2003)

Slides:

Advertisements

Similar presentations

O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.

Advertisements

Volume 144, Issue 1, Pages (January 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 150, Issue 1, Pages (July 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 145, Issue 2, Pages (May 2017)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis Takekazu Iwata, MD, PhD, Shigetoshi Yoshida,

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 152, Issue 1, Pages (January 2019)

Volume 141, Issue 2, Pages (May 2016)

Volume 135, Issue 1, Pages (October 2014)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 148, Issue 1, Pages (January 2018)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

L.M. Bean, F.J. Sulzmaier, D.D. Schlaepfer

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial Katsuyuki Kiura,

Volume 146, Issue 1, Pages (July 2017)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 150, Issue 1, Pages (July 2018)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer Yoshiko Oshiro, MD,

Volume 152, Issue 1, Pages (January 2019)

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 147, Issue 3, Pages (December 2017)

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Volume 152, Issue 1, Pages (January 2019)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] Heini Lassus,

Characteristics of primary peritoneal serous carcinoma in a U. S

Primary Small Cell Carcinoma of the Esophagus

Lymph Node Staging by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients With Small Cell Lung Cancer Hironobu Wada, MD, Takahiro.

Volume 147, Issue 3, Pages (December 2017)

Volume 124, Issue 1, Pages (January 2012)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 154, Issue 1, Pages (July 2019)

Joan L. Walker, M.D. Stephenson Cancer Center University of Oklahoma

Volume 115, Issue 1, Pages (October 2009)

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.

Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.

Presentation transcript:

Volume 91, Issue 3, (December 2003) Erratum to “First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up” Keiichi Fujiwara, Noriaki Sakuragi, Sachiko Suzuki, Nobutaka Yoshida, Kenichiro Maehata, Masashi Nishiya, Takayuki Koshida, Hideaki Sawai, Eriko Aotani, Ichiro Kohno Gynecologic Oncology Volume 91, Issue 3, (December 2003) DOI: 10.1016/j.ygyno.2003.09.006

Fig. 2 (a) Overall survival based on the dose of carboplatin (either <400 mg/m2 or ≥400 mg/m2) in patients with stage III/IV disease. (b) Overall survival based on the dose of carboplatin (either <400 mg/m2 or ≥400 mg/m2) in stage III/IV patients with residual disease <2 cm. (c) Overall survival based on the dose of carboplatin (either <400 mg/m2 or ≥400 mg/m2) in stage III/IV patients with residual disease ≥2 cm. Gynecologic Oncology 2003 91, DOI: (10.1016/j.ygyno.2003.09.006)